Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial

R. Kendall (Vancouver, Canada), S. Shukla (Collegeville, United States of America), A. Martin (Uxbridge, United Kingdom), D. Shah (New York, United States of America), D. Midwinter (Brentford, United Kingdom), I. Boucot (Brentford, United Kingdom), N. Risebrough (Toronto, United States of America), P. Jones (Brentford, United Kingdom), C. Compton (Brentford, United Kingdom), A. Ismaila (Collegeville, United States of America)

Source: Virtual Congress 2021 – Highlights for primary care in 2021
Session: Highlights for primary care in 2021
Session type: Oral Presentation
Number: 78

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Kendall (Vancouver, Canada), S. Shukla (Collegeville, United States of America), A. Martin (Uxbridge, United Kingdom), D. Shah (New York, United States of America), D. Midwinter (Brentford, United Kingdom), I. Boucot (Brentford, United Kingdom), N. Risebrough (Toronto, United States of America), P. Jones (Brentford, United Kingdom), C. Compton (Brentford, United Kingdom), A. Ismaila (Collegeville, United States of America). Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial. 78

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021
Year: 2022



Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
Year: 2021



Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018



Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009

Comparative efficacy of umeclidinium/vilanterol versus LABA/LAMA therapies in COPD: A network meta-analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016


Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018


Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study
Source: International Congress 2018 – COPD management
Year: 2018

INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012


Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD
Source: International Congress 2017 – COPD management
Year: 2017


Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001

IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain
Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence
Year: 2021



Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 1198; 10.1183/20734735.0279-2020
Year: 2021



Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
Source: International Congress 2018 – COPD management
Year: 2018


Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
Source: ERJ Open Res, 7 (1) 00816-2020; 10.1183/23120541.00816-2020
Year: 2021



Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017


Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018


Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020